AstraZeneca (AZ; NASDAQ: AZN) has reported data from a Phase II trial for its idiopathic pulmonary fibrosis (IPF) candidate, tralokinumab, which has contributed to the development of Brainomix’s e-Lung software. This AI-enabled tool, announced by the UK medtech company this week, is designed to identify patients at risk of decline by analyzing computed tomography (CT) images. The software stratifies patients by their risk of IPF progression, potentially enhancing the efficiency of future clinical trials through the strategic design of treatment arms and reducing trial size.
The e-Lung platform’s capabilities extend to identifying reticular opacities and vascular structures within the lung, allowing it to predict changes in forced vital capacity (FVC), lung function, and survival over the subsequent 52 weeks. The performance of this platform is noted to surpass that of standard methods, offering a significant advancement in the early identification of patients at risk of IPF decline.- Flcube.com
